Research across Embolism and Thrombosis
Related studies from across the Embolism and Thrombosis family.
Part of Embolism and Thrombosis
2 published articles · Updated continuously
13 trials tracked for central retinal vein occlusion: 7 in phase 3 or 4 and 5 with published results. The most-cited published study has 217 citations.
Showing the 13 most-cited and recently-updated of 13 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Treatment with aflibercept for central retinal vein occlusion has demonstrated significant improvements in visual acuity. In a Phase 4 study, 65.6% of participants achieved a gain of ≥15 letters in Best Corrected Visual Acuity (BCVA) on the ETDRS chart 1. Additional data showed mean BCVA improvements of approximately 18.4 to 18.9 letters at month 6 [2, 3], with a substantial number of eyes achieving scores of 70 or better 3.
Faricimab treatment also demonstrated measurable gains in visual acuity over 24 weeks, with approximately 56.6% to 58.1% of participants gaining ≥15 letters in BCVA 4. Ranibizumab has been utilized in multiple trials for this condition; while specific mean letter gains were reported as 11.3 or -2.7 depending on the study cohort, significant improvements in patient-reported outcomes (NEI-VFQ-25) were observed at months 3, 6, and 12 6.
Clinical evidence also indicates that aflibercept is associated with a mean change in the Panretinal Ischemic Index of 0.67 2.
AI synthesis of 5 cited trials, updated Jun 25, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
Related studies from across the Embolism and Thrombosis family.